News
15 September 2026
Immagina BioTechnology contributes to the growing field of dark proteome research.
The growing interest in unexplored areas of the human proteome is opening new opportunities to understand biology and discover potential therapeutic targets.
A recent article published in Nature Biotechnology highlights how scientists are studying the so-called “dark proteome”, a collection of previously overlooked protein-like molecules that may play important roles in human health and disease.
Using advanced computational and experimental approaches, researchers have identified thousands of potential new proteins that were missed by traditional methods. Many of these molecules originate from non-canonical open reading frames (ORFs), including small proteins and proteins encoded by RNA sequences previously considered non-coding.
The article describes how researchers are increasingly moving beyond the traditional proteome view towards the broader “translatome”, which includes all genomic RNA molecules that are translated by ribosomes into proteins. Technologies such as ribosome profiling (ribo-seq) are helping scientists identify previously unknown translation events and explore these hidden areas of biology.
Immagina BioTechnology is featured among the companies contributing to this emerging field. Based in Trento, Italy, Immagina provides products and services for ribosome profiling and other techniques used to explore the translatome and dark proteome.
As research continues to uncover new translated sequences, the dark proteome is becoming an important area for understanding cellular functions and identifying new opportunities in drug discovery. The ability to study these hidden proteins may help researchers discover new biological insights and potential therapeutic targets.
Source:
Eisenstein M. Startups mine ‘dark proteome’ for new drug targets. Nature Biotechnology, Volume 44, September 2026.
Explore how ribosome profiling can help uncover new layers of biological information.
Visit Immagina BioTechnology to learn more about our technologies and services.